Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811959 | 0.91 | BRD4 (0.43) | BRD4HTR6BCHEGPR119MET | |
| SCHEMBL31245972 | 0.90 | BRD4 (0.45) | BRD4HTR6BCHEGPR119MEN1 | |
| SCHEMBL30824838 | 0.90 | BRD4 (0.45) | BRD4HTR6BCHEGPR119MEN1 | |
| SCHEMBL30812007 | 0.85 | BRD4 (0.43) | BRD4HTR6BCHEGPR119 | |
| SCHEMBL30812210 | 0.84 | BRD4 (0.48) | BRD4HTR6BCHEGPR119CSF1R | |
| SCHEMBL30812171 | 0.83 | BRD4 (0.56) | BRD4 | |
| SCHEMBL30812319 | 0.83 | BRD4 (0.52) | BRD4HTR6 | |
| SCHEMBL30824889 | 0.83 | BRD4 (0.45) | BRD4HTR6 | |
| SCHEMBL30824921 | 0.82 | BRD4 (0.48) | BRD4HTR6GPR119MEN1KMT2A | |
| SCHEMBL31245982 | 0.81 | BRD4 (0.47) | BRD4HTR6BCHEGPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |